000 | 01674 a2200469 4500 | ||
---|---|---|---|
005 | 20250517025248.0 | ||
264 | 0 | _c20160512 | |
008 | 201605s 0 0 eng d | ||
022 | _a1949-2553 | ||
024 | 7 |
_a10.18632/oncotarget.3685 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aZhang, Fu-quan | |
245 | 0 | 0 |
_aJAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. _h[electronic resource] |
260 |
_bOncotarget _cJun 2015 |
||
300 |
_a14329-43 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
650 | 0 | 4 | _aDrug Resistance, Neoplasm |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 |
_aErbB Receptors _xgenetics |
650 | 0 | 4 |
_aErlotinib Hydrochloride _xpharmacology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aJanus Kinase 2 _xantagonists & inhibitors |
650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Nude |
650 | 0 | 4 |
_aPyrrolidines _xpharmacology |
650 | 0 | 4 |
_aSulfonamides _xpharmacology |
650 | 0 | 4 | _aXenograft Model Antitumor Assays |
700 | 1 | _aYang, Wen-tao | |
700 | 1 | _aDuan, Shan-zhou | |
700 | 1 | _aXia, Ying-chen | |
700 | 1 | _aZhu, Rong-ying | |
700 | 1 | _aChen, Yong-bing | |
773 | 0 |
_tOncotarget _gvol. 6 _gno. 16 _gp. 14329-43 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.3685 _zAvailable from publisher's website |
999 |
_c24800126 _d24800126 |